[ad_1]
Morkporkpor Anku / Kodjo Adams, RNG
Accra, May 31, GNA – Intravenous Infusions
PLC, Pharmaceutical Manufacturers, delivered a strong
performance in 2018 with revenues up more than 23.4% to GH ¢ 20.21 million
against 16.37 million GH ¢ in 2017.
Mr. David Klutse, Executive Director,
Intravenous Infusion PLC, stated that the after-tax operating profit for the year was
increase of 4% to 2.84 million GH ¢, compared with 2.73 million GH ¢ in
year.
Mr. Klutse at the company's annual conference
General Meeting in Accra stated that the reports shared with stakeholders indicated
that they were on the right track and that they were delivering their initial public offering
(IPO) commitments.
He added that the company had also identified six
strategic priorities that they believe would be critical to their success.
"We are taking steps to build more
efficiency and effectiveness in the way we work and in manufacturing, we are
adapting production capacity to our ever-evolving product line, "he added.
Mr. Klutse stated that the progress made in the
year under review highlights the benefits of the strategic choices they have made
in society in recent years to build a sustainable increase
capacity.
"We expect positive results from society
progress in the coming year as we are well positioned to generate high returns
our valuable shareholders, "he added.
He said that the external environment remained
very difficult with significant competitive pressures from importers of
intravenous (IV) therapy products in the country, significant delays by the
National Health Insurance Authority (NHIA) by paying for the hospital facilities of
a timely manner.
However, he said: "We believe that we have placed
society is well positioned to meet these challenges. Keeping our
we create value for our shareholders. "
Mr. Isaac Osei, Chairman of the Board of Directors,
Intravenous Infusions PLC, said the company had declared a dividend on a dividend of 0.00384 GH ¢
per share, which indicates that this is in line with the three-year forecast
at the stage of the IPO (2015) for the company to return to pay a dividend in three
years.
In 2018, the company strengthened its
operational efficiency to support their sales and profit growth to create
sustainable value for their shareholders and other stakeholders.
He said that these achievements have helped
that they achieve a new year of good performance with a sales increase of 23.4%.
% over one year and an improvement in pre-tax profit of 8.8% year-on-year.
The Chairman of the Board stated: "We were able to
improve our cash flow and earnings per share with the objective of
continue to create value for our shareholders. "
He said the company was also collaborating
with the relevant stakeholders in the new pricing policy to help facilitate the
charge on the national wallet while supporting the patient
access to quality health products.
Mr. Osei stated that the company was committed to
strict quality standards in the manufacture of their products, adding that
they appointed a pharmacovigilance officer in senior management
team to monitor the safety of their products on the market.
He said the company was constantly looking for ways
to improve their corporate governance, continue their commitment to the many
stakeholders such as shareholders, decision-makers, customers and
regulators as a whole.
He stated that the company, as part of its
strategic plan to restore its presence in the West African subregion
region and increase the contribution to total revenue to 5%.
Mr. Osei said the company was planning to increase
its turnover of 20.2 million GH ¢ to 24 million GH ¢, increases its market share
from 60% to 65%, introduce six new products and improve its efficiency.
use of 40 to 50%.
"The company will cooperate with the
Government to address the issue of imported rigid intravenous vials,
expansion to meet all regulatory requirements and to take into account operational funding
challenges of
NHIS by the government, "he said.
GNA
Source link
